Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COLT-HF
2023-506675-96-00Phase 3Authorised
- Sponsor
- Hamilton Health Sciences
- Start
- Jan 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, open-label trial of colchicine and thiamine in heart failure (HF) and coronary arteriosclerosis (4 arms), sponsored by Hamilton Health Sciences. Primary endpoints: Colchicine arm primary endpoint and Thiamine arm primary endpoint. Planned start Jan 2025; status: authorised.
02
Drugs
colchicinethiamine
03
Conditions
heart failure (HF)coronary arteriosclerosis
Beyond the preview
Go deeper on 2023-506675-96-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506675-96-00.